Asterand will apply its tools for compound profiling and target validation.
Asterand entered into a partnership with Bristol-Myers Squibb for access to Asterand’s products and services for up to three years. The agreement will focus on access to Asterand’s PhaseZERO® drug discovery services and Asterand’s XpressBANK™ of human tissue and clinical samples for the validation of early drug targets and support for compound optimization.
Asterand says its human tissue-based approach through PhaseZERO Services and XpressBANK Samples can help assist in the early identification of possible adverse events in humans and thus may help reduce the high attrition rates and costs associated with drug discovery and development.
Under this extended collaboration, Asterand will continue to undertake a range of PhaseZERO studies for Bristol-Myers Squibb in the areas of compound profiling and target validation. Likewise, Bristol-Myers Squibb will be granted access to Asterand’s XpressBANK of human tissue, bio-fluid, and cell lines and may also utilize Asterand’s ProCURE custom clinical sample collection service.